Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) has shared an announcement.
WuXi AppTec Co., Ltd. announced its unaudited interim results for the first half of 2025, showcasing significant financial growth. The company reported a 20.6% increase in revenue and a 95.5% rise in net profit attributable to owners compared to the previous year. The gross profit margin also improved to 43.8%. Additionally, the Board declared a mid-year dividend, reflecting the company’s strong performance and commitment to returning value to shareholders.
The most recent analyst rating on (HK:2359) stock is a Hold with a HK$51.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. is a global company operating across Asia, Europe, and North America. It provides a wide range of R&D and manufacturing services to the pharmaceutical and life sciences industry, facilitating the advancement of medical discoveries and treatments. The company’s offerings include chemistry drug CRDMO, biology discovery, preclinical testing, and clinical research services, aimed at enhancing the productivity of healthcare product development through cost-effective and efficient solutions.
Average Trading Volume: 6,901,492
Technical Sentiment Signal: Buy
Current Market Cap: HK$273.8B
For detailed information about 2359 stock, go to TipRanks’ Stock Analysis page.